Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 years or older;~2. Chronic AD that had been present for at least 3 years before the screening visit;~3. Patients with documented recent history (within 6 months before the screening visit) of inadequate response to out-patient treatment with topical medications, or for whom topical treatments were otherwise inadvisable;~4. Willing and able to comply with all clinic visits and study-related procedures.~Exclusion Criteria:~1. Prior participation in a Dupilumab clinical trial;~2. Treatment with an investigational drug within 8 weeks or within 5 half-lives before the baseline visit;~3. The following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, will likely require such treatment(s) during the first 4 weeks of study treatment:~   * Systemic corticosteroids;~  * Immunosuppressive/immunomodulating drugs;~  * Phototherapy for AD;~4. Treatment with topical corticosteroids, tacrolimus and/or pimecrolimus within 1 week before the baseline visit;~5. Treatment with certain biologics;~6. Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks before the baseline visit;~7. Planned major surgical procedure during the participant's participation in this study;~8. Participant was a member of the investigational team or his/her immediate family;~9. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit~10. Pregnant or breast-feeding women or women planning to become pregnant or breastfeed during the study;~Note: The information listed above is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial therefore not all inclusion/exclusion criteria are listed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo qw (Type: EXPERIMENTAL): Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
- Dupilumab 200 mg qw (Type: EXPERIMENTAL): Two subcutaneous injections of Dupilumab 200 milligram (mg) (for a total of 400 mg) as a loading dose on Day 1, followed by a single 200 mg injection qw from Week 1 to Week 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).